Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
  • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

• the present invention relates to a method of treatment or prophylaxis of insulin-producing cell graft rejection, particularly pancreatic islet graft rejection.
• Type 1 diabetes is caused by a progressive, autoimmune destruction of the insulin-producing ⁇ -cells within the islets of the pancreas.
• multiple daily insulin injections, or insulin pump therapy remain the treatments of choice for the majority of diabetic patients.
• Intensive insulin therapy can decrease the incidence of secondary complications, but the effect is not absolute and patients are at increased risk for serious episodes of hypoglycemia.
• Islet transplantation is a significantly safer method for replacing the diseased glandular tissue in diabetics than pancreatic organ transplantation, and has been investigated for more than 10 years as a treatment for type 1 diabetes mellitus in patients with inadequate glucose control despite intensive insulin therapy.
• islet engraftment has been difficult to achieve with such an immunosuppressive regimen due to rejection, recurrent autoimmunity, primary nonfunction (PNF), and the diabetogenicity of conventional immunosuppressive drugs.
• proinflammatory mediators produced by activated intrahepatic macrophages and endothelial cells subsequent to islet infusion, are detrimental to islet function and may lead to early islet loss or primary nonfunction of the graft.
• IEQ islet equivalents
• the present invention comprises a method for the treatment or prophylaxis of insulin-producing cell graft rejection in an insulin-producing cell graft recipient comprising co-administering to the recipient an effective amount of an accelerated lymphocyte homing (ALH) agent and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone, and a soluble human complement inhibitor.
• AHL accelerated lymphocyte homing
• the co-administration therapy of the invention is glucocorticoid-free.
• the invention comprises combined administration of an ALH agent, an antibody to the IL-2 receptor and an immunosuppressive macrocyclic lactone.
• such a treatment may additionally include administration of a soluble human complement inhibitor.
• the combination therapy of the invention facilitates engraftment, sustained insulin independence, and long-term survival of insulin-producing cell allo- or xenografts.
• a particular advantage of the present therapy is in facilitating single-donor transplants, which are less clinically challenging than multiple donor grafts, by effectively reducing the numbers of transplanted cells needed to provide functional insulin-producing cell mass in the patient.
• the present therapy can reduce the required number of islet equivalents (IEQ) to 5,000 mg/kg per recipient, or less.
• insulin independence is meant endogenous insulin production as determined after intravenous glucose tolerance test to the extent that the subject has normal glucose tolerance.
• insulin-producing cell is meant islets of Langerhans (of allo or xeno origin) and other cells such as suitable insulin-secreting cells or cell lines, e.g. stem cell derived or cloned insulin-secreting cells.
• the present invention also provides:
• an ALH agent in free form or in pharmaceutically acceptable salt form in combination with one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor, to treat or prevent insulin-producing cell graft rejection.
• a pharmaceutical combination comprising a) an ALH agent in free form or in pharmaceutically acceptable salt form, and b) one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor.
• pharmaceutical combination preferably includes a non-fixed combination, e.g. the active components are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific limits, wherein such administration provides therapeutically effective levels of the components in the body of the patient.
• Each active component may be administered in the form of a pharmaceutical composition, e.g. the active component is associated with one or more pharmaceutically acceptable diluents or carriers therefor.
• an ALH agent in free form or in pharmaceutically acceptable salt form, in the manufacture of a medicament for use in treating or preventing insulin-producing cell graft rejection in an insulin-producing cell graft recipient, in combination with one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor.
• the ALH agent is administered in combination with an immunosuppressive macrocyclic lactone, optionally together with a soluble human complement inhibitor; alternatively, the ALH agent may be administered in combination with an immunosuppressive macrocyclic lactone and an antibody to the IL-2 receptor, optionally together with a soluble human complement inhibitor.
• the ALH agents of the invention are compounds which may be phosphorylated by sphingosine kinase and are in the phosphorylated form potent agonists at S1P receptors, thereby modulating lymphocyte trafficking, e.g. synthetic analogs of myriocin or ISP-1 , a natural metabolite of the ascomycete Isaria sinclairii.
• ALH agent include e.g. 2-aminopropane1-3-diol compounds, e.g. a compound of formula I
• R T is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene,
• R 2 is H or a residue of formula
• R 6 is H or C 1-4 alkyl optionally substituted by 1 , 2 or 3 halogen atoms
• R 7 is H or
• R 3 is H or C ⁇ alkyl, and each of R» and R 5 , independently, is H; C M alkyl optionally substituted by halogen; or acyl, in free form or in pharmaceutically acceptable salt form.
• the carbon chain as R ⁇ is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy.
• the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted.
• the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.
• Acyl may be a residue R-CO- wherein R is C 1-6 alkyl, Cs- ⁇ cycloalkyl, phenyl or phenyl-C 1- alkyl.
• Preferred compounds of formula I are those wherein Ri is a straight or branched, preferably straight, chain alkyl having 13 to 20 carbon atoms, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein R, is phenylalkyl substituted by a straight or branched C 6 . 14 -alkyl chain optionally substituted by halogen and the alkyl moiety is a C h alky! optionally substituted by hydroxy. More preferably, Ri is phenyl-C 1-6 alkyl substituted on the phenyl by a straight or branched, preferably straight, C 6 . alkyl chain. The C ⁇ 3 - ⁇ 4 alkyl chain may be in ortho, eta or para, preferably in para.
• each of R 2 to R 5 is H.
• Examples of pharmaceutically acceptable salts of the compounds of the formula (I) include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine.
• the compounds and salts of the methods of the present invention encompass hydrate and solvate forms.
• a preferred compound of formula I is 2-amino-2-tetradecyl-1,3-propanediol.
• a particularly preferred ALH compound for use in the invention is FTY720, j ⁇ 2-amino-2-[2-(4- octylphenyl) ethyl] propane- 1 ,3-diol in free form or in a pharmaceutically salt form, e.g.the hydrochloride, as shown:
• R 2 is H, or its corresponding phosphate, wherein R 2 is
• FTY720 a novel immunomodulator, increases the responsiveness of lymphocytes to homing chemokines. Naive cells are sequestered; CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP), and infiltration of cells into transplanted organs is inhibited.
• LN lymph nodes
• PP Peyer's patches
• FTY720 does not impair lymphocyte activation, expansion and memory within the lymphoid system, and therefore does not suppress immunity to systemic infection.
• the anti-IL-2 receptor antibody of the invention is preferably an antibody to the high affinity receptor for IL-2, ie ⁇ CD25.
• Suitable antibodies comprise native or recombinant antibodies, and include recombinant chimeric or humanized antibodies, as well as recombinant single chain polypeptides consisting of a native antibody binding (i.e. Fv) domain, e.g. basiliximab (SimulectTM), which is a chimeric antibody comprising the variable region of murine monoclonal antibody CHI-621 and a human lgG1 region, see EP 449,769, incorporated herein by reference, or daclizumab (Zenapax R ), see WO 90/07,861 incorporated herein by reference.
• a particularly preferred antibody is basiliximab.
• rapamycin By “immunosuppressive macrocyclic lactone” is meant rapamycin, Le. sirolimus, and immunosuppressant derivatives thereof.
• rapamycin derivatives which are substituted in position 40 (or 42 or 43 depending on the nomenclature used), e.g. 40-O-substituted rapamycin derivatives as described in U.S. Patent No., 5,258,389 and WO 94/09010, especially 40-O-alkylated rapamycin derivatives, e.g. wherein the 40-O- substituent is hydroxyalkylated, e.g. 40-O-(2-hydroxyethyl) rapamycin, i.e.
• 40-O-(2-hydroxyethyl) rapamycin is particularly preferred.
• Suitable soluble complement inhibitor includes e.g. a C3/C5 inhibitor, e.g. a soluble complement receptor type I (CR1), TP-10, which is a recombinant protein that is a potent systemic inhibitor of the complement system, since it blocks both C3 and C5 activation by all three activation pathways (classical, alternative, and lectin); and it is subsequent to C3 activation that the majority of complement-dependent effector mechanisms are recruited.
• TP-10 binds C3b and C4b, activation fragments of the complement system, blocking their interaction with other proteins in the complement cascade and subsequently the formation of multi-molecular enzyme complexes which generate the biologically active protein fragments of complement.
• TP-10 also acts as a co-factor in the enzymatic degradation of C3b and C4b to their inactive forms.
• TP-10 is a modified CR1 molecule lacking the transmembrane and cytoplasmic domains, e.g. as disclosed in WO 89/09220, incorporated herein by reference.
• TP-10 is expressed by Chinese hamster ovary (CHO) cells in serum-free media and purified on anti-CR1 affinity columns and by HPLC.
• Administration of TP10 to islet transplant recipients was reported by Bennett, et. al., Diabetes 2000.
• a soluble complement receptor inhibitor suitable for use in the invention comprise TP-20, a combined complement and selectin inhibitor that integrates sCR1 (soluble complement receptor-1) with the sLex (sialyl Lewis x) carbohydrate in a single molecule; and TP-18, an sCR1 derivative inserted into a selectin-(receptor)-blocking carbohydrate.
• Daily dosages of the therapeutic agents required in practicing the method of the present invention will vary, depending upon for example the ALH agent employed, the host, the mode of administration, the severity of the condition to be treated, and the further selected therapeutic agents used in combined administration.
• co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single transplant recipient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
• the ALH agent e.g., FTY720
• administration of the ALH agent be commenced preoperatively.
• the compound may be administered starting from just prior to the day the transplant operation is carried out (i.e. "Day 0"), for example starting on Day -1 , and continuing indefinitely thereafter.
• the compound may be administered e.g. orally or by injection.
• a preferred daily dosage range for the ALH agent e.g. a compound of formula I (e.g, FTY720) is about from 0.03 to 2.5 mg/kg per day, particularly 0.1 to 2.5 mg/kg per day, e.g. 0.5 to 2.5 mg/kg per day as a single dose or in divided doses.
• Suitable daily dosages for patients are in the order of from e.g. 0.25 to 100 mg p.o.
• Suitable unit dosage forms for oral administration of a compound of formula I comprise from ca. 0.125 to 10 mg together with one or more pharmaceutically acceptable diluents or carriers therefor.
• the compound of formula I in free form or in pharmaceutically acceptable salt form may also be administered twice or three times a week, e.g.
• the ALH agent e.g. the compounds of formula I
• Pharmaceutical compositions comprising the compounds of formula I may be manufactured in conventional manner, e.g. as described in U.S. Patent No. 5,604,229.
• the anti-IL2 receptor antibody e.g., basiliximab
• the anti-IL2 receptor antibody is preferably administered in a two-dose regimen, the first dose being administered on Day 0 (i.e. day of transplant) and a second on about Day 4. Additionally doses following about Day 4 may optionally be administered, e.g. once weekly for 2 to 4 weeks.
• each dose is generally about 1 to 50 mg, and preferably about 5 to 20 mg.
• the immunosuppressive macrocyclic lactone e.g., 40-O-2-(hydroxyethyl)-rapamycin
• suitable doses are in the range of 0.25 - 7 mg /day, and more particularly 0.5 - 5 mg /day.
• the compound may be administered orally or alternatively by subcutaneous injection.
• the soluble complement receptor e.g., TP-10, can be administered in single dosages of about 5 to 15 mg/kg, preferably about 10 mg/kg, as an intravenous infusion over about 30 minutes.
• the invention is directed to a glucocorticoid-free combination therapy for use in connection with insulin-producing cell transplantation, e.g. pancreatic islet cell transplantation, comprising co-administration of an ALH agent, such as in particular a compound of formula I, e.g. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form, preferably the hydrochloride salt thereof; in combination with one or more of basiliximab, 40-O-(2-hydroxyethyl)-rapamycin and the soluble recombinant human complement inhibitor, sCR1 ("TP10").
• ALH agent such as in particular a compound of formula I, e.g. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form, preferably
• the therapeutic methods of the invention may optionally include co-administration of still other immunomodulating drugs or anti-inflammatory agents, examples of which may comprise a calcineurin inhibitor, e.g. cyclosporins or ascomycins, and their immunosuppressive analogs, e.g.
• immunosuppressive monoclonal antibodies e.g., monoclonal antibodies to leukocyte receptors, e.g., to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD
• the methods of the invention may be employed as a prophylaxis or treatment of insulin- producing cell allograft or xenograft rejection.
• FTY720 The compound is prepared for administration by emptying the contents of a capsule (1 mg/capsule) in a 60 mL clear glass mortar. 30 mL of sterile water are added and mixed with the capsule content until the powder is in a uniform suspension. The FTY720 is administered orally using a syringe and a nasogastric tube.
• Basiliximab The material is obtained as a package containing 20 mg of powder in a vial and a second vial containing 5 mL of diluent. Each vial is formulated according to the manufacturer's instructions and administered i.v. accordingly.
• Everolimus The compound is obtained as a concentrate of 20 mg/ml in a sealed ampoule. 1 ml of the concentrate is mixed with 8.5 ml vehicle (50% Cremophor and 50% ethanol) to give a final concentration of 2.1 mg/ml (pH 6.0) and the mixture is used within 2 hours.
• TP10 the material is obtained as 50 mg multi-dose vials (no formulation required).
• Pancreatectomy of donor animals Donor animals are adult cynomolgus monkeys over 4 kg, of either sex. Prior to pancreatectomy, fasting serum glucose analysis and aginine stimulation are performed to assure normal endocrine pancreatic function. For arginine stimulation, 0.07 mg/kg arginine are injected intravenously, and blood collected at -5, -1 , 2, 3, 4, and 5 minutes after arginine injection. Plasma is collected and stored frozen at -80°C. Plasma insulin and C-peptide levels are confirmed to be within normal range.
• Pancreatectomy is performed under general anaesthesia with 0.5 to 2% isofluorane, and the pancreas is harvested. Lymph nodes and spleen are also harvested for donor lymphocyte isolation and cryopreservation. Following organ and tissue harvest the donor is euthanized with 150 mg/Kg of Na pentobarbital i.v., and cardiac arrest confirmed by visual inspection.
• Islet isolation Islet isolation is performed using modifications of the automated method for human islet isolation, as described by Ricordi et al., Diabetes. 38. (Suppl.1): 140-142, 1989; Kenyon et al., Diabetes.48, pp. 8132-8137, 1999; and Ranuncoli et al., Cell Transplantation 2000.
• Islet quality assessment is performed according to international standards ⁇ Ricordi, Gray, et al. 1990 13 /id ⁇ , including determination of islet yield, purity, and viability.
• IEQ islet equivalents
• DTZ dithizone
• Purity is estimated based on the percentage of DTZ positive particles present in the preparation, and viability is estimated based on FDA/PI staining.
• n vitro functional capacity is determined via assessment of glucose stimulated insulin release in static cultures (see Ranuncoli et. al., Cell Transplantation, 2000).
• Recipient animals are juvenile cynomolgus monkeys of > 1.5 kg, of either sex. Recipient animals are rendered diabetic by infusion of streptozotocin (STZ), 150 mg/kg i.v., followed by intravenous hydration (20 ml/kg of 0.9% NaCI over 30 minutes) to prevent nephrotoxic side effects, as described by Theriault Thistlethwaite et al., 1999, 16 /id. Blood glucose level is monitored frequently during the first 48 hours after streptozotocin application to avoid severe hypoglycemia or hyperglycemia with eventual ketoacidosis.
• STZ streptozotocin
• blood sugar levels are monitored 2-3 times daily and corrected with Regular, NPH, Lente, Ultralente, or Humalog insulin via subcutaneous injection or intravenous insulin-drip, as needed.
• Induction of diabetes is confirmed by daily blood glucose measurements, assessment of insulin requirements and by a negative C- peptide value subsequent to arginine stimulation.
• an arginine stimulation test is performed prior to initiation of immunosuppression.
• 0.07 mg/kg arginine is injected intravenously, and blood collected - 5, -1, 2, 3, 4, 5 min. after arginine injection. Plasma is collected and stored frozen at -80°C.
• Plasma glucose is measured using a Cobas Mira glucose analyzer (Roche Diagnostic Systems, Montclair, NJ).
• a double antibody method (Diagnostic Products, Corp., Los Angeles, CA) is utilized to assess plasma insulin and C-peptide levels.
• the lower limit of detection for C-peptide is 0.20 ng/ml and for insulin is 5 uU/ml. Standard curves, as well as positive and negative control samples are incorporated into the assays.
• Sedated and anaesthetized recipient animals are placed supine on the operating table and the abdomen is prepped and draped. Special attention is paid to avoid hypothermia and a heat lamp and heating pads are used.
• a small central midline incision is made and a minimum of 10,000 freshly isolated islet equivalents/kg body weight are resuspended in 20 ml of transplant media and infused into a mesenteric tributary of the portal vein through a 24- gauge intravenous catheter.
• the vessel is either ligated or digital pressure is applied.
• the abdominal wall is closed in a routine fashion. Blood glucose is monitored twice each day and arginine stimulation tests are performed to document reversal of the diabetic state.
• Group 1 FTY720 + everolimus + basiliximab, 10,000 lEQ/kg body weight.
• Group 2 FTY720 + everolimus + basiliximab, 5,000 lEQ/kg body weight.
• Group 3 FTY720 + everolimus + basiliximab + TP10, 5,000 lEQ/kg body weight.
• Recipient animals in the indicated groups receive the following treatments prior to and following the day of transplant (Day "0") as detailed below: FTY720 is administered p.o at 0.3 mg/kg, day -1 through day +30.
• Basiliximab is administered by intravenous injection at 10 mg on day 0 and day 4.
• the recommended dose is in the range of 0.075 mg/kg/day.
• TP10 is administered by intravenous injection at a dosage level of 40 mg/kg on day -1 , 20 mg/kg on days 0 and 1, and 17 mg/kg from days 2 to 7.
• the recipient animals are dosed at approximately the same time each morning and in the afternoon when applicable. Blood glucose levels are determined frequently over the first 4-5 hours post-transplant to prevent hypoglycemic episodes. Such episodes are treated with dextrose 5-10% intravenously as needed. The presence of rejection is suspected if three consecutive fasting blood glucose levels rise above 150 mg/dl or three post-prandial blood glucose levels of more than 200 mg/dl are recorded. Rejection is assumed if these levels are present 3 days in a row. Thereafter, fasting and post-prandial blood glucose (fasting blood glucose, post-prandial glucose) levels are monitored 2-3 times a day via heel stick.
• Ultralente Humalog insulin via subcutaneous injection according to an individualized sliding scheme.
• An arginine stimulation test is performed at 14 days and 1 month posttransplant and at additional time points thereafter.
• the pathology of the graft organ is evaluated. Routine H&E stained sections are evaluated histologically. In this model, the combined treatment with FTY720, everolimus and basiliximab prevents islet allograft rejection.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Diabetes (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Biomedical Technology (AREA)
• Cell Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Transplantation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23144725

Family Applications (1)

Country Status (18)

Cited By (4)

Families Citing this family (18)

Family Cites Families (6)

• 2002
  • 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
  • 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
  • 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
  • 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
  • 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
  • 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
  • 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
  • 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
  • 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
  • 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
  • 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
  • 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
  • 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
  • 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
  • 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
  • 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
• 2003
  • 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
  • 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
• 2006
  • 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
• 2008
  • 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
• 2011
  • 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
• 2013
  • 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events